Affiliations: Department of Pharmacology Poznan University of
Medical Sciences, Poznan, Poland
Note: [] Corresponding author: Marzena Dworacka, Department of
Pharmacology Poznan University of Medical Sciences, Rokietnicka 5a, 61-701
Poznan, Poland. Tel.: +48 61 8694 395; Fax: +48 61 8694 481; E-mail:
mdworac@am.poznan.pl
Abstract: Aim: Recent data have suggested that effective control of
postprandial blood glucose can reduce the risk of macroangiopathic
complications of diabetes, especially cardiovascular risk.
1,5-Anhydro-D-glucitol (1,5-AG) has been proposed as a marker of short-term
hyperglycaemic excursions. We aimed to evaluate its usefulness in patients with
type 2 diabetes and have attempted to indicate when 1,5-AG monitoring should be
used in ordinary diabetes care settings. Methods: The study group consisted of 130 type 2 diabetic patients
aged 36–69 years. 1,5-AG plasma level, HbA_1c
concentrations and daily glucose profile were measured. Mean blood glucose
(MBG), M-value were calculated and maximal daily glycaemia (MxG) was
established as indicators of short-term hyperglycaemic episodes. Results: 1,5-AG plasma level was negatively and
HbA_1c was positively correlated with fasting glycaemia
(FG), MBG, M-value and MxG. Multivariate regression analysis revealed that
1,5-AG plasma level is determined by MxG only, while FG determined
HbA_1c concentration in blood. The analysis of 1,5-AG level
and HbA_1c distributions in well and poorly controlled
patients revealed that persons with low HbA_1c values may
have decreased 1,5-AG plasma level. Conclusion: 1,5-AG plasma level monitoring is the useful method to
identify well controlled, exclusively based on HbA_1c levels
type 2 diabetic patients with transient hyperglycaemia, accordingly patients at
high risk of macroangiopathic complications
Keywords: 1,5-anhydro-D-glucitol, glycated haemoglobin, postprandial hyperglycaemia, diabetes mellitus type 2
